

Sartorius Stedim Biotech launches the Sartocon® ECO ultrafilter

Sartorius Stedim Biotech S.A.
Z.I. Les Paluds
Avenue de Jouques
B.P. 1051
13781 Aubagne, France

www.sartorius-stedim.com

Goettingen, June 03, 2010 - Sartorius Stedim Biotech GmbH, a leading international biopharmaceutical supplier, has expanded its array of ultrafilters by the Sartocon® ECO series of ultrafilters. Sartocon® ECO ultrafilters have been developed for biotechnological and pharmaceutical purification processes in the industry for the manufacture of vaccines and monoclonal antibodies.

Sartocon® ECO is based on Hydrosart® ultrafilter technology that uses stabilized polymer membranes based on hydrophilic regenerated cellulose. Hydrosart® membranes enable especially high yields by minimizing protein binding to the membrane and are thus virtually non-fouling. As Sartocon® ECO features high stability under strongly alkaline conditions and over wide temperature ranges, it is not only easy to clean but also reusable even after several cleaning cycles, considerably reducing operating costs. In addition, Sartocon® ECO filters provide constant process performance, allowing process parameters to be maintained in existing crossflow systems.

"There are a few, but specific requirements that high-performance ultrafilters must meet: high yield, minimal adsorption, complete cleanability and compatible use in existing crossflow systems. With the Sartocon® ECO ultrafilter series, we are providing production managers and process developers with a product that optimally fulfills these requirements," explains Frank Meyeroltmanns, Head of Product Management, Crossflow, at Sartorius Stedim Biotech.

Sartocon® ECO ultrafilters will be available in Slice, Sartocon® and Sartocube® formats for preferred nominal molecular weight cutoffs of 10kD, 30kD and 100kD in a cassette design.

Image/Photo File:



Photo Caption:

Sartocon® ECO ultrafilter cassettes for economical process designing.

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions".

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approximately 2,400 people, and in 2009 earned sales revenue of 401.2 million euros.

Contacts: Dominic Grone; Sartorius Group Corporate Communications
Sartorius Corporate Administration GmbH; 37070 Goettingen, Germany
Phone: +49(0)551/ 308-3324 or -3684; fax: +49(0)551/ 308-3572;
E-mail: dominic.grone@sartorius.com; www.sartorius-stedim.com